JOHNSON JOHN — SEC Form 4 filings
SEC reporting owner CIK 1410781. 20 Form 4 filings on record with FilingPulse; latest filed 2026-06-26.
Transaction summary — filings shown
Covers all 20 filings on record, filed 2024-03-13 to 2026-06-26. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 9 legs across 6 filings — 318,402 shares, $3,766,476 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 33.
- Largest priced transaction: sale of 135,400 shares @ $7.22 ($977,019) in Xeris Biopharma Holdings, Inc., filed 2025-12-19.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Axogen, Inc. (AXGN) | Director | 8 | — | 6 legs · 60,502 sh · $1,911,575 | 14 |
| Xeris Biopharma Holdings, Inc. (XERS) | Director | 7 | — | 3 legs · 257,900 sh · $1,854,901 | 7 |
| Verastem, Inc. (VSTM) | Director | 4 | — | — | 10 |
| Applied Therapeutics, Inc. (APLT) | Executive Chairman, Director | 1 | — | — | 2 |
Form 4 filings — JOHNSON JOHN
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-26 | 4 | Axogen, Inc. (AXGN) | Grant/award (A): 4,392 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Axogen, Inc. (AXGN) | Option exercise (M): 14,150 @ $0 · Option exercise (M): 14,150 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 15,000 @ $6.09 · Grant/award (A): 24,193 @ $0 · Grant/award (A): 32,996 (derivative) @ $6.15 | EDGAR |
| 2026-05-26 | 4 | Verastem, Inc. (VSTM) | Grant/award (A): 36,000 @ $0 | EDGAR |
| 2026-05-08 | 4 | Axogen, Inc. (AXGN) | Option exercise (M): 11,050 @ $7.04 · Sale (S): 11,050 @ $43.26 · Option exercise (M): 11,050 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 135,400 @ $7.22 | EDGAR |
| 2025-12-10 | 4 | Axogen, Inc. (AXGN) | Sale (S): 11,802 @ $31.26 · Option exercise (M): 11,891 @ $6.30 · Sale (S): 11,891 @ $31.22 · Option exercise (M): 8,545 @ $6.30 · Sale (S): 8,545 @ $29.98 · Sale (S): 13,141 @ $29.98 · +2 more | EDGAR |
| 2025-08-15 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Sale (S): 107,500 @ $7.32 | EDGAR |
| 2025-06-20 | 4 | Axogen, Inc. (AXGN) | Grant/award (A): 14,150 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Axogen, Inc. (AXGN) | Sale (S): 4,073 @ $10.61 | EDGAR |
| 2025-06-04 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2025-05-27 | 4 | Verastem, Inc. (VSTM) | Grant/award (A): 8,333 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-12-20 | 4 | Applied Therapeutics, Inc. (APLT) | Grant/award (A): 500,000 @ $0 · Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | Axogen, Inc. (AXGN) | Option exercise (M): 11,904 @ $0 · Option exercise (M): 11,904 (derivative) @ $0 | EDGAR |
| 2024-06-20 | 4 | Verastem, Inc. (VSTM) | Grant/award (A): 8,333 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Axogen, Inc. (AXGN) | Grant/award (A): 10,653 · Grant/award (A): 18,248 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2024-04-01 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Other (J): 89,571 | EDGAR |
| 2024-03-18 | 4 | Xeris Biopharma Holdings, Inc. (XERS) | Option exercise (M): 215,600 @ $1.99 · Option exercise (M): 215,600 (derivative) @ $0 | EDGAR |
| 2024-03-13 | 4 | Verastem, Inc. (VSTM) | Disposition to issuer (D): 2,083 (derivative) · Disposition to issuer (D): 2,083 (derivative) · Disposition to issuer (D): 2,300 (derivative) · Disposition to issuer (D): 2,083 (derivative) · Grant/award (A): 8,549 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1410781 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →